Fig. 1From: Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective studyFrequency and reasons for the use of polyethylene glycol-conjugated granulocyte colony-stimulating factor (PEG-G-CSF)Back to article page